8-K: Arcellx Inc. Changes Independent Auditor from Ernst & Young to PricewaterhouseCoopers

Arcellx Inc. has dismissed Ernst & Young as their independent auditor and appointed PricewaterhouseCoopers, effective March 8, 2024.

Summary

• Arcellx Inc. has changed its independent registered public accounting firm from Ernst & Young LLP (EY) to PricewaterhouseCoopers LLP (PwC), effective March 8, 2024.
• The dismissal of EY was approved by the Board of Directors upon the recommendation of the Audit Committee.
• The change was not due to any disagreements with EY regarding accounting principles, financial statement disclosures, or auditing procedures.
• EY's reports on the company's financial statements for the fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinions or disclaimers.
• There were no disagreements or reportable events between the company and EY, except for a previously reported material weakness in internal controls over financial reporting which was remediated by December 31, 2022.
• PwC was engaged as the new independent auditor for the fiscal year ending December 31, 2024, following the execution of an engagement letter on March 13, 2024.
• Arcellx did not consult with PwC on any matters related to accounting principles or auditing procedures prior to their appointment.

Sentiment

Score: 7

Explanation: The document indicates a routine change of auditors with no underlying issues, which is generally neutral to positive. The remediation of the material weakness is a positive sign.

Positives

• The change in auditors was not due to any disagreements on accounting or auditing matters, suggesting a smooth transition.
• EY's audit reports for 2022 and 2023 were clean, indicating no issues with the company's financial statements.
• A previously reported material weakness in internal controls was remediated by December 31, 2022, showing improvement in the company's financial processes.

Risks

• The transition to a new auditor could present some short-term challenges as PwC becomes familiar with Arcellx's financial systems and processes.
• Although the material weakness was remediated, any future issues with internal controls could raise concerns.

Future Outlook

The company will be working with PwC for the fiscal year ending December 31, 2024.

Management Comments

• The Board of Directors approved the dismissal of EY and the engagement of PwC based on the recommendation of the Audit Committee.
• The dismissal of EY was not related to any disagreements on accounting or auditing matters.

Industry Context

Changes in auditors are not uncommon, but it is important that the transition is smooth and does not indicate any underlying issues with the company's financials. The fact that there were no disagreements with EY is a positive sign.

Comparison to Industry Standards

• The change of auditors is a normal business practice, and many companies switch auditors periodically for various reasons, including cost, expertise, or rotation policies.
• Companies like Amgen, Gilead, and Regeneron, which are also in the biotech space, have also changed auditors in the past, often without any negative implications.
• The fact that Arcellx's previous auditor, EY, had no disagreements with the company is consistent with industry best practices for a smooth transition.

Stakeholder Impact

• Shareholders may view the change of auditors as a routine matter, especially given the lack of disagreements with the previous auditor.
• The smooth transition to a new auditor should reassure stakeholders about the company's financial reporting processes.

Next Steps

• PwC will conduct the audit for the fiscal year ending December 31, 2024.

Key Dates

Keywords

auditor, accounting, Ernst & Young, PricewaterhouseCoopers, financial statements, internal controls, audit, Arcellx